← Back to Search

Procedure

MRI Screening for High-Risk Breast Cancer Detection

N/A

Recruiting

Led By Mohammed Shazeeb, PhD

Research Sponsored by University of Massachusetts, Worcester

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1.5 years (duration of patient recruitment and outcome data collection)

Awards & highlights

Study Summary

This trial is testing a deep learning model, Mirai, to accurately predict breast cancer risk. It will compare cancer outcomes between patients identified as high-risk by Mirai vs. existing guidelines and study its impact by race/ethnicity.

Who is the study for?

This trial is for women over 40 identified as high risk for breast cancer using the Mirai model or traditional guidelines. They must have had a mammogram at Umass sites with results in the EHR and be willing to undergo an MRI. Pregnant women, those under 40, men, and anyone with poor quality mammogram images are excluded.Check my eligibility

What is being tested?

The MIRAI-MRI study is testing if screening MRIs based on high-risk assessments from a new AI model called Mirai can better detect breast cancer compared to current standards. It involves comparing outcomes of patients identified by Mirai against those by traditional methods.See study design

What are the potential side effects?

While not directly related to side effects, undergoing an MRI may involve discomfort due to the enclosed space and loud noises during the procedure. There's also a small risk of allergic reaction to contrast agents used in some MRIs.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1.5 years (duration of patient recruitment and outcome data collection)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1.5 years (duration of patient recruitment and outcome data collection)

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1.5 years (duration of patient recruitment and outcome data collection) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

CDR Mirai Assessment versus CDR Traditional High Risk Screening

Secondary outcome measures

Cancer development within study population versus general population of average risk women

Trial Design

1Treatment groups

Experimental Treatment

Group I: Breast MRI Screening for High Risk PatientsExperimental Treatment1 Intervention

Breast MRI will be recommended for patients who are deemed high risk by either the traditional model (Tyrer Cusick) or the Mirai model.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Massachusetts, WorcesterLead Sponsor

343 Previous Clinical Trials

986,110 Total Patients Enrolled

5 Trials studying Breast Cancer

38,384 Patients Enrolled for Breast Cancer

Mohammed Shazeeb, PhDPrincipal InvestigatorUMass Chan Medical School

Media Library

Breast MRI (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05968157 — N/A

Breast Cancer Research Study Groups: Breast MRI Screening for High Risk Patients

Breast Cancer Clinical Trial 2023: Breast MRI Highlights & Side Effects. Trial Name: NCT05968157 — N/A

Breast MRI (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05968157 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any openings in this clinical experiment that potential participants can take advantage of?

"According to clinicaltrials.gov, the initial posting of this trial was on August 1st 2023 and it has not been recruiting patients since being edited on July 21st 2023. Nevertheless, there are 2,654 other medical studies taking in participants at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-Cuzick

Mohammad Salman Shazeeb 2023. "MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-Cuzick". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05968157.